SEC Form 4 · accession 0001179110-19-000534

IDERA PHARMACEUTICALS, INC. · IDRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Medical Officer

Period of report

Jan 3, 2019

Accepted (ET)

Jan 7, 2019 · 8:24 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000861838

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jan 3, 2019	A	18,100	$0.00	A	20,144	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$3.14	Jan 3, 2019	A	45,500	A	—	Jan 3, 2029	Common Stock	45,500	45,500	D

F1Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award.
F2Securities beneficially owned totaling 20,144 includes 2,044 shares of Issuer common stock owned and 18,100 of unvested RSU's held by the reporting person.
F3The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 3, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.